诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NVO 诺和诺德

休市中 07-26 16:00:00 EDT

126.73

-1.13

-0.88%

盘后126.90

+0.17+0.13%

19:59 EDT

最高128.26	最低126.36	成交量317.91万
今开126.86	昨收127.86	日振幅1.49%
总市值5,620亿	流通市值4,015亿	总股本44.35亿
成交额4.05亿	换手率0.10%	流通股本31.68亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"NVO","market":"US","secType":"STK","nameCN":"诺和诺德","latestPrice":126.73,"timestamp":1722024000000,"preClose":127.86,"halted":0,"volume":3179137,"hourTrading":{"tag":"盘后","latestPrice":126.8954,"preClose":126.73,"latestTime":"19:59 EDT","volume":72217,"amount":9152610.4897,"timestamp":1722038396601},"delay":0,"floatShares":3168268189,"shares":4434515173,"eps":2.879408,"marketStatus":"休市中","marketStatusCode":7,"change":-1.13,"latestTime":"07-26 16:00:00 EDT","open":126.86,"high":128.26,"low":126.36,"amount":404525345.43512,"amplitude":0.01486,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.879408,"exchange":"NYSE","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1722240000000},"adr":1,"listingDate":363499200000,"adjPreClose":127.86,"adrRate":1,"dividendRate":0.010916,"preHourTrading":{"tag":"盘前","latestPrice":126.99,"preClose":127.86,"latestTime":"09:29 EDT","volume":56786,"amount":7244371.962344,"timestamp":1722000599355},"postHourTrading":{"tag":"盘后","latestPrice":126.8954,"preClose":126.73,"latestTime":"19:59 EDT","volume":72217,"amount":9152610.4897,"timestamp":1722038396601},"volumeRatio":0.863301,"impliedVol":0.433,"impliedVolPercentile":0.9722},"requestUrl":"/m/hq/s/NVO","defaultTab":"news","newsList":[{"id":"2454328180","title":"美国 FDA 就诺和诺德减肥药复方制剂的剂量错误发出警告","url":"https://stock-news.laohu8.com/highlight/detail?id=2454328180","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454328180?lang=zh_cn&edition=full","pubTime":"2024-07-26 21:57","pubTimestamp":1722002243,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透7月26日 - 美国食品和药物管理局周五就诺和诺德  减肥药和糖尿病药复方制剂的剂量错误问题向患者和医生发出警告。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4007","BK4532","LU1093756325.SGD","NVO","LU0154236417.USD","BK4588","LU1093756168.USD","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD"],"gpt_icon":1},{"id":"2454331883","title":"诺和诺德(NVO)盘前升近1% Wegovy适应症范围扩大 中风等心血管疾病风险降低20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2454331883","media":"金吾财讯","labels":["Product Release","Policy And Regulatory"],"top":-1,"share":"https://www.laohu8.com/m/news/2454331883?lang=zh_cn&edition=full","pubTime":"2024-07-26 16:51","pubTimestamp":1721983903,"startTime":"0","endTime":"0","summary":"金吾财讯 | 诺和诺德(NVO)股价盘前扬升，暂涨0.93%，报129.05美元。欧洲药品管理局(EMA)支持该公司的Wegovy用于降低没有糖尿病的超重或肥胖成年人的主要心脏病和中风风险。诺和诺德表示，将在大约一个月内更新Wegovy在欧盟的标签或处方信息。一项后期试验的数据表明，与安慰剂相比，Wegovy将心脏病发作和中风等主要心血管事件的风险降低了20%，这也支持了Wegovy扩大适应症范围。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210625/ZTU2NWU2NGY4ODMxNzMwNDYxNzE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/ZTU2NWU2NGY4ODMxNzMwNDYxNzE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"278235","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release,Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO","IE00BKVL7J92.USD","BK4585","BK4588","BK4532","BK4007","IE00BZ1G4Q59.USD","LU0154236417.USD","LU1093756168.USD","LU1093756325.SGD"],"gpt_icon":1},{"id":"2454397022","title":"心脏病风险降低20%！诺和诺德(NVO.US)减肥药Wegovy在欧盟斩获新适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2454397022","media":"智通财经","labels":["Policy And Regulatory"],"top":-1,"share":"https://www.laohu8.com/m/news/2454397022?lang=zh_cn&edition=full","pubTime":"2024-07-26 16:37","pubTimestamp":1721983067,"startTime":"0","endTime":"0","summary":"诺和诺德表示，将在大约一个月内更新Wegovy在欧盟的标签或处方信息。一项后期试验的数据表明，与安慰剂相比，Wegovy将心脏病发作和中风等主要心血管事件的风险降低了20%，这也支持了Wegovy扩大适应症范围。诺和诺德表示，该试验在41个国家招募了17604名成年人。本月以来，诺和诺德股价下跌逾10%，礼来下跌逾9%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1156061.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LLY","IE00BKVL7J92.USD","NVO","BK4532","BK4007","BK4585","IE00BZ1G4Q59.USD","LU1093756168.USD","LU1093756325.SGD","LU0154236417.USD","BK4588"],"gpt_icon":1},{"id":"1136187782","title":"不止“减肥药双雄”，基金经理点名存在估值机会的股票，并称市场大到可以容纳三到四家公司","url":"https://stock-news.laohu8.com/highlight/detail?id=1136187782","media":"老虎资讯综合","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/1136187782?lang=zh_cn&edition=full","pubTime":"2024-07-26 11:45","pubTimestamp":1721965537,"startTime":"0","endTime":"0","summary":"减肥药在过去一年左右引起了投资者的兴趣，并撼动了其他行业。Tema ETFs的基金经理Yuri Khodjamirian表示，这两家公司构成了一个“非常强大的双头垄断”。“我认为市场大到可以容纳三到四家公司，即使是现在已经存在的市值，但市场正在试图找出第三或第四个玩家，而一个重大的突破可能是口服GLP-1药物，”他说。GLP-1是一种在肠道中释放的激素，能刺激胰岛素分泌，延缓胃排空并向大脑传递饱腹感。他说，目前生物技术股票存在“估值机会”，但也警告了风险。","market":"us","thumbnail":"https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMGN","VKTX","NVO","LLY"],"gpt_icon":1},{"id":"1155648411","title":"Viking Therapeutics暴涨近30%，最新研究可能撼动减肥药市场，吓坏两大市场巨头","url":"https://stock-news.laohu8.com/highlight/detail?id=1155648411","media":"老虎资讯综合","labels":["analysis"],"top":-1,"share":"https://www.laohu8.com/m/news/1155648411?lang=zh_cn&edition=full","pubTime":"2024-07-26 07:36","pubTimestamp":1721950589,"startTime":"0","endTime":"0","summary":"$Viking Therapeutics$ 的股票在周四飙升28.31%，因为该公司宣布正在研究其减肥药的每月剂量。此前，Viking计划进行二期B阶段的研究。两家公司分别通过Zepbound和Wegovy主导减肥药市场，但它们的每周注射药物面临短缺，这意味着竞争对手有机会进入市场。而Viking是首个宣布潜在每月注射方案的公司。Viking Therapeutics股票表现强劲 Viking Therapeutics的消息对礼来的股票特别不利。他对Viking Therapeutics的股票给予了“优于大盘”的评级。口服减肥药市场也在升温。","market":"us","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Viking Therapeutics减肥药物研究取得重大进展,股价大涨28%","news_tag":"analysis","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LLY","NVO","VKTX"],"gpt_icon":1},{"id":"2454638501","title":"减肥药领域接近变天？Viking Therapeutics盘中暴涨近40%，礼来市值缩水1200亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2454638501","media":"华尔街见闻","labels":["Product Release"],"top":-1,"share":"https://www.laohu8.com/m/news/2454638501?lang=zh_cn&edition=full","pubTime":"2024-07-26 03:13","pubTimestamp":1721934790,"startTime":"0","endTime":"0","summary":"美国Viking Therapeutics在与监管机构FDA沟通后，超预期推进减肥候选药物VK2735至三期临床试验，或令上市时间提前一年，这款药物预计每个月注射一次，比礼来与诺和诺德的同款神药更方便，VK2735口服版将在今年四季度开启中期试验。再结合瑞士罗氏制药在同领域的利好消息，令礼来在八个交易日内累跌14%，为2020年以来最差，市值较峰值缩水超1200亿美元。","market":"us","thumbnail":"https://wpimg-wscn.awtmt.com/652981f0-2f6c-4475-97ee-17fbaf58c3f6.jpeg","type":0,"news_type":0,"thumbnails":["https://wpimg-wscn.awtmt.com/652981f0-2f6c-4475-97ee-17fbaf58c3f6.jpeg"],"rights":{"source":"wallstreetcn_hot_news","url":"https://wallstreetcn.com/articles/3721227","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3721227","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"wallstreetcn_hot_news","symbols":["LU0417517546.SGD","LU0097036916.USD","LU0238689110.USD","IE00BK4W5L77.USD","LENZ","IE00BK4W5M84.HKD","LU0114720955.EUR","LU1023059063.AUD","LU0689472784.USD","LU1267930730.SGD","LU0385154629.USD","BK4585","LU0672654240.SGD","LU0823416689.USD","GB00BDT5M118.USD","LU0882574139.USD","LU0079474960.USD","LU1623119135.USD","LU0820561818.USD","NVO","BK4139","LU0882574055.USD","IE0002141913.USD","LU1551013425.SGD","LU1804176565.USD","LU0198837287.USD","LU0256863902.USD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","LU1064131342.USD","LU0466842654.USD","IE0009355771.USD","LU0820561909.HKD","BK4007","LU0471298777.SGD","BK4516","LU1061106388.HKD","LU0320765059.SGD","IE00BFTCPJ56.SGD","LU0456855351.SGD","LU0096364046.USD","LU1551013342.USD","LU0256863811.USD","LU0640476718.USD","LU1069344957.HKD","BABA","LU1712237335.SGD","BK4588","LU0289739699.SGD","BK4581","LU0943347566.SGD"],"gpt_icon":1},{"id":"2454801639","title":"获欧盟批准！诺和诺德减肥药Wegovy能降低20%的重大心脏病风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2454801639","media":"华尔街见闻","labels":["Policy And Regulatory"],"top":-1,"share":"https://www.laohu8.com/m/news/2454801639?lang=zh_cn&edition=full","pubTime":"2024-07-26 00:22","pubTimestamp":1721924528,"startTime":"0","endTime":"0","summary":"据诺和诺德公告，欧洲药品管理局（EMA）支持该公司将减肥药Wegovy用于降低中风和心脏病风险。分析认为，此举显著扩大了其潜在受益患者的数量。欧洲药品管理局（EMA）的药物咨询小组在本周四宣布，这一决定是基于诺和诺德支持的一项大型研究。该研究显示，Wegovy能够将主要心脏疾病的风险降低20%。在全球范围内，心脏病目前...","market":"hk","thumbnail":"https://inews.gtimg.com/om_ls/OYA4QUN1MwzDfQulRdGjHzgUey-DH7sRM_2ipXnhrhEOYAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OYA4QUN1MwzDfQulRdGjHzgUey-DH7sRM_2ipXnhrhEOYAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240726A004XL00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240726A004XL00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["LU0154236417.USD","LU1093756325.SGD","BK4532","BK4007","LU1093756168.USD","BK4585","IE00BZ1G4Q59.USD","NVO","BK4588","IE00BKVL7J92.USD"],"gpt_icon":1},{"id":"2454805643","title":"诺和诺德减肥药Wegovy可将重大心脏病风险降低20%，欧盟：支持拓宽用途","url":"https://stock-news.laohu8.com/highlight/detail?id=2454805643","media":"华尔街见闻","labels":["Policy And Regulatory"],"top":-1,"share":"https://www.laohu8.com/m/news/2454805643?lang=zh_cn&edition=full","pubTime":"2024-07-25 23:40","pubTimestamp":1721922048,"startTime":"0","endTime":"0","summary":"更多消息，持续更新中","market":"hk","thumbnail":"https://wpimg-wscn.awtmt.com/d0/24/94/-1-2-.png","type":0,"news_type":0,"thumbnails":["https://wpimg-wscn.awtmt.com/d0/24/94/-1-2-.png"],"rights":{"source":"wallstreetcn_hot_news","url":"https://wallstreetcn.com/articles/3721219","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3721219","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"wallstreetcn_hot_news","symbols":["IE00BKVL7J92.USD","BK4532","BK4588","IE00BZ1G4Q59.USD","LU0154236417.USD","LU1093756325.SGD","NVO","BK4007","BK4585","LU1093756168.USD"],"gpt_icon":1},{"id":"2454038388","title":"欧盟监管机构支持使用诺和诺德的 Wegovy 降低心脏风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2454038388","media":"Reuters","labels":["Policy And Regulatory"],"top":-1,"share":"https://www.laohu8.com/m/news/2454038388?lang=zh_cn&edition=full","pubTime":"2024-07-25 23:16","pubTimestamp":1721920617,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透7月25日 - 诺和诺德公司周四表示，欧洲药品管理局委员会支持使用诺和诺德的  Wegovy降低心脏风险。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","BK4585","NVO","BK4007","BK4588","IE00BZ1G4Q59.USD","LU0154236417.USD","LU1093756168.USD","BK4532","IE00BKVL7J92.USD"],"gpt_icon":1},{"id":"2454606803","title":"诺和诺德：欧洲药品管理局就Wegovy在重大心血管不良反应方面体现出降低风险的表现给出积极意见","url":"https://stock-news.laohu8.com/highlight/detail?id=2454606803","media":"国际金融报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454606803?lang=zh_cn&edition=full","pubTime":"2024-07-25 23:15","pubTimestamp":1721920505,"startTime":"0","endTime":"0","summary":"诺和诺德表示，欧洲药品管理局(EMA)就“(减肥药)Wegovy在重大心血管不良反应方面体现出降低风险”的表现给出积极意见。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240725231512af942144&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240725231512af942144&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","IE00BKVL7J92.USD","LU0154236417.USD","BK4007","NVO","LU1093756168.USD","BK4588","BK4532","IE00BZ1G4Q59.USD","LU1093756325.SGD"],"gpt_icon":1},{"id":"2454842006","title":"全球第一家万亿美元市值的医药公司呼之欲出","url":"https://stock-news.laohu8.com/highlight/detail?id=2454842006","media":"证券市场周刊","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454842006?lang=zh_cn&edition=full","pubTime":"2024-07-25 17:31","pubTimestamp":1721899865,"startTime":"0","endTime":"0","summary":"文丨刘翎在英伟达、苹果、微软等公司争夺全球最大市值上市公司的过程中，医药板块有家公司，凭借自身卓越的研发能力和长远布局，可能会成为全球第一家市值超过万亿美元的医药上市公司。礼来公司成立于1876年，在其悠久且卓越的公司历史上，其是世界上第一家大规模生产胰岛素的公司。目前，礼来公司产品覆盖精神疾病、心血管、肿瘤、自免等领域，是一家全球知名的平台型医药公司。全球预计超过2000亿美元。全球患者预计将近5000万人。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407251735469ee97405&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407251735469ee97405&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BJJMRZ35.SGD","LU1064131342.USD","LU0238689110.USD","LU0114720955.EUR","LU0689472784.USD","LU0154236417.USD","LU0256863902.USD","LU0640476718.USD","BK4588","LU0820561818.USD","LU0256863811.USD","LU1093756325.SGD","NVO","LU1551013342.USD","LU1623119135.USD","IE00BKVL7J92.USD","LU1267930730.SGD","IE00B2B36J28.USD","LU0417517546.SGD","BK4581","IE0009355771.USD","LU0096364046.USD","LU0198837287.USD","IE00B4R5TH58.HKD","LU0456855351.SGD","GB00BDT5M118.USD","IE00BJLML261.HKD","LU0820561909.HKD","LU0672654240.SGD","IE00BZ1G4Q59.USD","BK4585","IE0002141913.USD","LU0320765059.SGD","LU0943347566.SGD","LU0882574055.USD","LU0079474960.USD","LU0385154629.USD","LU0466842654.USD","LU0882574139.USD","LU0471298777.SGD","LU1061106388.HKD","LU1069344957.HKD","LU1712237335.SGD","LU0823416689.USD","LLY","IE00BFTCPJ56.SGD","LU0097036916.USD","BK4516","LU1804176565.USD","LU1551013425.SGD"],"gpt_icon":1},{"id":"2453013741","title":"诺和诺德(NVO.US)减肥药Wegovy获得英国监管部门批准 可用于治疗心脏病","url":"https://stock-news.laohu8.com/highlight/detail?id=2453013741","media":"智通财经","labels":["Product Release","Policy And Regulatory"],"top":-1,"share":"https://www.laohu8.com/m/news/2453013741?lang=zh_cn&edition=full","pubTime":"2024-07-24 08:45","pubTimestamp":1721781900,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，继美国之后，英国监管部门也批准扩大诺和诺德减肥药Wegovy的适用范围至治疗心脏病。该减肥药成为该国首个用于预防肥胖人群心血管事件的处方药。诺和诺德的重磅产品Wegovy注射剂已经在英国获得批准，用于治疗肥胖和体重管理，与饮食、体育活动和行为支持一起使用。然而，新的批准标志着该公司寻求摆脱Wegovy作为“虚荣药”的形象，并抵御日益激烈的竞争。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1154765.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"减肥药Wegovy获批预防心脏病 诺和诺德再下一城","news_tag":"Product Release,Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BKVL7J92.USD","BK4532","BK4588","IE00BZ1G4Q59.USD","LU0154236417.USD","LU1093756325.SGD","NVO","BK4007","BK4585","LU1093756168.USD"],"gpt_icon":1},{"id":"2453068787","title":"诺和诺德拟在丹麦新建工厂 或用于扩大减肥药产能","url":"https://stock-news.laohu8.com/highlight/detail?id=2453068787","media":"媒体滚动","labels":["Product Release"],"top":-1,"share":"https://www.laohu8.com/m/news/2453068787?lang=zh_cn&edition=full","pubTime":"2024-07-24 01:17","pubTimestamp":1721755062,"startTime":"0","endTime":"0","summary":"财联社7月23日讯 当地时间周二，丹麦制药巨头诺和诺德宣布，本月早些时候在丹麦第三大城市欧登塞买下了一块200英亩的土地，并获得了规划许可。虽然诺和诺德并未透露这块土地的用途，但从已有信息来看，该公司可能会将其用于扩大减肥药的产能。丹麦去年经济增长了近2%，但如果没有诺和诺德的贡献，丹麦经济可能会停滞不前。","market":"us","thumbnail":"https://n.sinaimg.cn/finance/transform/162/w550h412/20240724/1d69-d0a310409cadb7ec1bab5a36700d963a.jpg","type":0,"news_type":0,"thumbnails":["https://n.sinaimg.cn/finance/transform/162/w550h412/20240724/1d69-d0a310409cadb7ec1bab5a36700d963a.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/world/2024-07-23/doc-incfeeas7757129.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["BK4532","LU1093756168.USD","NVO","BK4588","BK4007","IE00BZ1G4Q59.USD","LU1093756325.SGD","BK4585","IE00BKVL7J92.USD","LU0154236417.USD"],"gpt_icon":1},{"id":"2453034143","title":"诺和诺德(NVO)或在丹麦新建工厂","url":"https://stock-news.laohu8.com/highlight/detail?id=2453034143","media":"金吾财讯","labels":["Product Release"],"top":-1,"share":"https://www.laohu8.com/m/news/2453034143?lang=zh_cn&edition=full","pubTime":"2024-07-23 21:07","pubTimestamp":1721740031,"startTime":"0","endTime":"0","summary":"金吾财讯 | 诺和诺德(NVN)宣布，已成功获取了位于丹麦第三大城市奥登塞的一块土地及其规划批准，用于建设其下一个重要的生产设施，此举旨在应对其减肥药品需求的急剧增长。该公司在本月初与奥登塞市政府达成了土地购买协议，并在市政府批准其规划方案后，成功购入了约200英亩的土地。诺和诺德的一位发言人透露，公司计划很快在这片土地上启动前期的挖掘工程。同时，该发言人还指出，在经过公司内部的评估之后，预计将在今年年底前对是否在新地点进行投资做出最终决策。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210625/ZGFjNmMxNjJiOWZlZTExMTI2OTIxOTcyMDA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/ZGFjNmMxNjJiOWZlZTExMTI2OTIxOTcyMDA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"278110","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO","IE00BKVL7J92.USD","BK4585","BK4588","BK4532","BK4007","IE00BZ1G4Q59.USD","LU0154236417.USD","LU1093756168.USD","LU1093756325.SGD"],"gpt_icon":1},{"id":"2453008209","title":"诺和诺德(NVO.US)或在丹麦新建工厂 已获得土地及规划许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2453008209","media":"智通财经","labels":["Product Release"],"top":-1,"share":"https://www.laohu8.com/m/news/2453008209?lang=zh_cn&edition=full","pubTime":"2024-07-23 18:52","pubTimestamp":1721731941,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺和诺德周二表示，该公司已经为其在丹麦第三大城市Odense的下一个主要工厂获得了土地和规划许可，以满足市场对其减肥药不断飙升的需求。诺和诺德一位发言人表示，该公司将很快开始在该地点进行预备挖掘工作。诺和诺德尚未透露该新址的用途。据悉，诺和诺德正努力增加其降糖药和减肥药的供应。今年6月，诺和诺德表示，预计今年将在生产上投资68亿美元，高于2023年的39亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1154572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BKVL7J92.USD","BK4585","BK4588","LU0154236417.USD","LU1093756168.USD","IE00BZ1G4Q59.USD","NVO","LU1093756325.SGD","BK4532","BK4007"],"gpt_icon":1},{"id":"2453705500","title":"诺和诺德在丹麦欧登塞购置地块，有望年底做出最终投资决定","url":"https://stock-news.laohu8.com/highlight/detail?id=2453705500","media":"界面","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453705500?lang=zh_cn&edition=full","pubTime":"2024-07-23 14:53","pubTimestamp":1721717603,"startTime":"0","endTime":"0","summary":"7月23日消息，诺和诺德于本月初在丹麦第三大城市欧登塞购买了一块200英亩的土地。诺和诺德发言人示，公司将很快开始在该地块南部启动准备性挖掘工作，经过内部审查后，公司将于今年年底就是否投资新地块做出最终决定。（彭博）","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240723145323af93940b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240723145323af93940b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4585","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU1093756168.USD","BK4532","NVO","LU1093756325.SGD","BK4007","LU0154236417.USD"],"gpt_icon":0},{"id":"2453772496","title":"诺和诺德或将在丹麦再建一座工厂，已获得土地和规划许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2453772496","media":"环球市场播报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453772496?lang=zh_cn&edition=full","pubTime":"2024-07-23 13:43","pubTimestamp":1721713413,"startTime":"0","endTime":"0","summary":"$诺和诺德$公司已经为其在丹麦的下一个主要工厂获得了土地和规划许可，以满足对其减肥药不断飙升的需求。诺和诺德正积极增加其糖尿病和减肥药物的供应。在过去的14个月里，该公司已宣布在丹麦、法国和美国投资数十亿美元扩建工厂。欧登塞距离丹麦首都哥本哈根只有大约两个小时的车程，这将是诺和诺德的一个新地点。该工厂距离Kalundborg不到60英里，后者是诺和诺德畅销药物Ozempic和Wegovy的关键原料生产地。","market":"hk","thumbnail":"https://static.tigerbbs.com/bde7ae9d5c597eb01bbb4658f0573654","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/bde7ae9d5c597eb01bbb4658f0573654"],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/usstock/c/2024-07-23/doc-incfawif0448260.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2024-07-23/doc-incfawif0448260.shtml","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["NVO"],"gpt_icon":0},{"id":"2453768407","title":"美股减肥药板块走势分化 诺和诺德(NVO.US)、礼来(LLY.US)双头垄断格局面临挑战","url":"https://stock-news.laohu8.com/highlight/detail?id=2453768407","media":"智通财经","labels":["Product Release"],"top":-1,"share":"https://www.laohu8.com/m/news/2453768407?lang=zh_cn&edition=full","pubTime":"2024-07-22 18:50","pubTimestamp":1721645400,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，7月以来，美股减肥药板块走势分化。市场领导者诺和诺德、礼来股价均走低，而实力较强的追赶者罗氏、辉瑞、安进在7月分别累计上涨13%、7%和6%。诺和诺德将于美东时间8月8日公布第二季度业绩。市场对减肥药的火爆需求推动诺和诺德第一季度净利润同比增长28%，该公司还上调了全年营收与经营利润增速指引。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1154025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0061475181.USD","BK4533","LU0882574139.USD","IE0002141913.USD","LU0471298694.HKD","LU0882574055.USD","BK4585","IE00BJLML261.HKD","IE0009355771.USD","IE00BKVL7J92.USD","BK4534","LU1551013425.SGD","LU0820561818.USD","PFE","IE00B1BXHZ80.USD","LU0096364046.USD","GB00BDT5M118.USD","LU1712237335.SGD","LU0708995401.HKD","LU1093756325.SGD","LLY","LU1280957306.USD","LU0823416689.USD","LU1551013342.USD","BK4516","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","NVO","LU0820561909.HKD","IE0004445239.USD","LU0385154629.USD","LU1069344957.HKD","LU1061106388.HKD","LU0079474960.USD","BK4007","LU0122379950.USD","LU1804176565.USD","LU0466842654.USD","LU1093756168.USD","BK4532","LU0114720955.EUR","LU0943347566.SGD","LU0094547139.USD","LU0097036916.USD","LU0109391861.USD","LU0058720904.USD","LU0256863811.USD","LU0689472784.USD","LU1035775433.USD","LU1623119135.USD"],"gpt_icon":1},{"id":"2453786850","title":"最高减重20%！礼来“替尔泊肽”在华获批，效果强过司美格鲁肽？","url":"https://stock-news.laohu8.com/highlight/detail?id=2453786850","media":"格隆汇","labels":["Product Release","Policy And Regulatory"],"top":-1,"share":"https://www.laohu8.com/m/news/2453786850?lang=zh_cn&edition=full","pubTime":"2024-07-22 10:20","pubTimestamp":1721614814,"startTime":"0","endTime":"0","summary":"竞争白热化？","market":"hk","thumbnail":"https://img3.gelonghui.com/1b662-9eab396d-85aa-4a35-807e-33d8ee710c4d.jpg?guru_height=908&guru_width=1280","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/1b662-9eab396d-85aa-4a35-807e-33d8ee710c4d.jpg?guru_height=908&guru_width=1280"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/869192","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release,Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK0175","BK4532","IE00BJJMRZ35.SGD","LU0114720955.EUR","BK0188","BK0239","IE00B1BXHZ80.USD","LU0058720904.USD","000963","LU0061475181.USD","LU0256863811.USD","BK0187","IE00BJT1NW94.SGD","LU1093756325.SGD","LU1551013342.USD","LU1623119135.USD","LU2328871848.SGD","603087","BK4007","NVO","LU0094547139.USD","LU0708995401.HKD","LU0096364046.USD","IE0009355771.USD","LU0109391861.USD","LU0122379950.USD","GB00BDT5M118.USD","IE00BJLML261.HKD","LU0471298694.HKD","LU0820561909.HKD","LI","IE0002141913.USD","LU0943347566.SGD","LU1035775433.USD","LU1061106388.HKD","LU0882574055.USD","BK4533","LU0079474960.USD","LU0385154629.USD","LU1280957306.USD","BK4534","IE0004445239.USD","BK0183","LU1093756168.USD","300199","BK0077","LU0097036916.USD","BK4516","LU1804176565.USD","LU1551013425.SGD"],"gpt_icon":1},{"id":"2452062894","title":"减肥药赛道“搅局者”来了，两大巨头“硬碰硬”","url":"https://stock-news.laohu8.com/highlight/detail?id=2452062894","media":"中国基金报","labels":["Product Release"],"top":-1,"share":"https://www.laohu8.com/m/news/2452062894?lang=zh_cn&edition=full","pubTime":"2024-07-20 00:16","pubTimestamp":1721405811,"startTime":"0","endTime":"0","summary":"国内减重赛道迎来重磅级“选手”。7月19日，记者从国家药品监督管理局获悉，礼来的替尔泊肽注射液长期体重管理适应证获得批准，这是目前首个且是唯一获批的葡萄糖依赖性促胰岛素多肽（GIP）/胰高糖素样肽-1（GLP-1）受体激动剂，也是礼来肥胖治疗领域在中国获批的首个创新药物。一直以来，礼来与诺和诺德并称“GLP-1双雄”，后者拥有“减肥神药”司美格鲁肽，已在国内获批上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202407203135777061.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202407203135777061.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4532","LU1093756168.USD","NVO","LLY","BK4588","BK4007","IE00BZ1G4Q59.USD","LU1093756325.SGD","BK4585","IE00BKVL7J92.USD","LU0154236417.USD"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.novonordisk.com","stockEarnings":[{"period":"1week","weight":-0.0366},{"period":"1month","weight":-0.1179},{"period":"3month","weight":-0.0009},{"period":"6month","weight":0.1727},{"period":"1year","weight":0.6179},{"period":"ytd","weight":0.225}],"compareEarnings":[{"period":"1week","weight":-0.0083},{"period":"1month","weight":-0.002},{"period":"3month","weight":0.0712},{"period":"6month","weight":0.117},{"period":"1year","weight":0.2032},{"period":"ytd","weight":0.1454}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Novo Nordisk A/S于1989年成立，由两家丹麦公司，诺德根措夫特A/S和Novo工业A/S的合并而成。诺和诺德是一家全球性医疗保健公司，糖尿病治疗的全球领先者。公司拥有业界最广泛的糖尿病产品组合，其中包括新一代胰岛素，现代的完整产品组合，以及作为一个人每日一次的GLP-1类似物之一。此外，诺和诺德在血友病关怀，生长激素疗法和激素替代疗法中也处于领先地位。","yearOnYearQuotes":[{"month":1,"riseRate":0.534884,"avgChangeRate":0.122207},{"month":2,"riseRate":0.604651,"avgChangeRate":0.027007},{"month":3,"riseRate":0.465116,"avgChangeRate":0.01259},{"month":4,"riseRate":0.627907,"avgChangeRate":0.016402},{"month":5,"riseRate":0.545455,"avgChangeRate":0.017073},{"month":6,"riseRate":0.704545,"avgChangeRate":0.027554},{"month":7,"riseRate":0.5,"avgChangeRate":0.004558},{"month":8,"riseRate":0.511628,"avgChangeRate":0.000647},{"month":9,"riseRate":0.581395,"avgChangeRate":0.000639},{"month":10,"riseRate":0.511628,"avgChangeRate":-0.000902},{"month":11,"riseRate":0.627907,"avgChangeRate":0.028932},{"month":12,"riseRate":0.744186,"avgChangeRate":0.054828}],"exchange":"NYSE","name":"诺和诺德","nameEN":"Novo-Nordisk A/S"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺和诺德(NVO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺和诺德,NVO,诺和诺德股票,诺和诺德股票老虎,诺和诺德股票老虎国际,诺和诺德行情,诺和诺德股票行情,诺和诺德股价,诺和诺德股市,诺和诺德股票价格,诺和诺德股票交易,诺和诺德股票购买,诺和诺德股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺和诺德(NVO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}